Cancer

63 studies in Cancer

  1. A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer
    1. Arizona
    2. Minnesota
  2. Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
    1. Arizona
  3. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
    1. Minnesota
  4. Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
    1. Arizona
  5. Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML
    1. Arizona
    2. Minnesota
  6. Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
    1. Arizona
  7. A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
    1. Arizona
    2. Minnesota
  8. A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
    1. Minnesota
  9. An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    1. Minnesota
  10. MC1351: PROstate Cancer Medically Optimized Genome Enhanced ThErapy-I (PROMOTE-I)
    1. Arizona
    2. Florida
    3. Minnesota
  1. Prev
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. Next
Jan. 02, 2014